Trial Profile
A single-arm, open phase II clinical trial of Piamprizumab injection plus platinum-containing chemotherapy combined with anrotinib hydrochloride capsules in first-line treatment of persistent, recurrent or metastatic cervical cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Catequentinib (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; Penpulimab (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 11 Dec 2023 New trial record
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress